Neuronetics targets $40M-$43M Q4 revenue as SPRAVATO mix drives full-year outlook
Source: SeekingAlpha
2025-11-04 12:29:59 ET
More on Neuronetics
- Neuronetics, Inc. (STIM) Q3 2025 Earnings Call Transcript
- Neuronetics GAAP EPS of -$0.13 in-line, revenue of $37.3M misses by $0.55M
- Seeking Alpha’s Quant Rating on Neuronetics
- Historical earnings data for Neuronetics
- Financial information for Neuronetics
Read the full article on Seeking Alpha
For further details see:
Neuronetics targets $40M–$43M Q4 revenue as SPRAVATO mix drives full-year outlook
Neuronetics Inc.
NASDAQ: STIM
STIM Trading
2.28% G/L:
$1.2887 Last:
250,118 Volume:
$1.29 Open:
STIM Latest News
March 03, 2026 08:30:00 am
Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call
February 10, 2026 04:34:49 pm
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
November 20, 2025 08:30:00 am
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
November 12, 2025 10:33:00 am
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
STIM Stock Data
$103,071,313
37,324,827
5.78%
18
N/A
Medical Diagnostics & Screening
Healthcare
US
Malvern
